MannKind's Afrezza Inhalation Powder Gets FDA Approval for Updated Dosage Guidance

MannKind Corporation announced the FDA approval of an updated prescribing information for Afrezza (insulin human) Inhalation Powder. The revised recommendations provide clearer starting dose guidance for patients switching from subcutaneous mealtime insulin regimens to inhaled insulin. This update is expected to support healthcare providers in transitioning patients to inhaled insulin.